Borderline personality disorder. Borderline personality disorder
Conditions
Interventions
Intervention 1: The placebo group will receive a placebo for 12 weeks. At the end of weeks 2, 4, 6, and 8, BPD symptoms will be evaluated by the Best test. Blood samples will be gathered before the i
Sponsors
Iran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
16 Years to 45 Years
Inclusion criteria
Inclusion criteria: Women or men between the ages of 16 and 45 who have been diagnosed with BPD using the BEST tool for the disease.
Exclusion criteria
Exclusion criteria: Clinical evidence of any pathology in the central nervous system, neurological disorders, head injuries, epilepsy or history of seizures Pregnancy or breastfeeding Taking medications that may interact with memantine
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum levels of memantine. Timepoint: Measurement of serum levels of memantine at the beginning of the study (before the intervention) and at the end of the treatment period. Method of measurement: High Performance Liquid Chromatograpy.;Symptoms. Timepoint: beginning of the study (before the intervention) and At the end of weeks 2, 4, 6 and 8. Method of measurement: The Best test. | — |
Secondary
| Measure | Time frame |
|---|---|
| Number of suicides. Timepoint: At the beginning of the study (before the intervention) and at the end of the intervention. Method of measurement: interview with patients. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactFariba Karimzadeh
Iran University of Medical Sciences
Outcome results
None listed